HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a price target of $30.

June 04, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Olema Pharmaceuticals and maintained a price target of $30, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $30 by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Olema Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100